depacon and Zolinza Interactions

Interactions between depacon(valproic acid) and Zolinza (vorinostat)

valproic acid and vorinostat (Major Drug-Drug)

MONITOR CLOSELY: Severe thrombocytopenia and gastrointestinal bleeding have been reported during concomitant use of vorinostat and other histone deacetylase (HDAC) inhibitors such as valproic acid, presumably due to additive pharmacodynamic effects.

MANAGEMENT: Blood cell counts, including platelets, should be performed every two weeks during the first two months of vorinostat therapy, then monthly thereafter. If abnormalities develop, the dosage should be reduced or therapy discontinued.